CD274 (PD-L1) Methylation is an Independent Predictor for Bladder Cancer Patients' Survival. (16th March 2022)

• Record Type: Journal Article
• Authors: Xu, Jing; Wei, Laiming; Liu, Hao; Lei, Yu; Zhu, Yanzhe; Liang, Chaozhao; Sun, Guoping
• Is Part Of: Cancer investigation. Volume 40:Number 3(2022)
• Page Start: 228
• Page End: 233
• Publication Date: 2022-03-16
• Subjects: CD274 -- PD-L1 -- methylation -- survival -- immunotherapy; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.1080/07357907.2022.2028805
• Languages: English
• ISSNs: 0735-7907

Abstract

Abstract: This study was carried out to demonstrate the prognostic value of CD274 (PD-L1 promoter gene) methylation in bladder cancer patients. UCSC Xena database was searched for relevant information on PD-L1 (CD274) methylation and PD-L1 mRNA expression in bladder cancer. 407 bladder patients were included in our analyses. Multivariate analysis revealed that PD-L1 methylation was an independent predictor for OS ( P = 0.037). Moreover, PD-L1 methylation might be a prognostic biomarker for immunotherapy response. However, PD-L1 methylation and PD-L1 mRNA expression was not statistically associated with chemotherapy response. In conclusion, PD-L1 methylation was an independent prognostic factor for bladder cancer patients.